Official websites use. Share sensitive information only on official, secure websites. GT was the lead author of the Commission and participated in the writing, editing and review of all sections. TMH was the senior author and participated in the writing of the Introduction, was the Conclusion lead, and edited and reviewed all sections. The Introduction lead author was PM. Subsection I lead author was SPI. Subsection V lead author was Av-K. JS reviewed in detail the entire manuscript providing editorial and content feedback.
All authors on the Commission reviewed and approved the final version of the Commission. Tremendous progress in treatment and outcomes has been achieved across the spectrum of haematologic malignancies over the last two decades. While cure rates for aggressive malignancies have risen, nowhere has progress been more impactful than in the management of typically incurable forms of haematologic cancer.
Population-based data have demonstrated substantial improvement in five-year survival rates for chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma. This has resulted from substantial changes in disease management strategies in these malignancies.
Several haematologic malignancies are now experienced by patients as chronic illnesses treated with chronically administered therapies that bear unique side effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events AEs in haematologic malignancies. The issues pertaining to AE assessment examined here are relevant across a spectrum of malignancies and have been, to date, underexplored in the context of hematology.
This international collaborative effort aims to improve toxicity assessment in clinical trials in haematologic malignancies by critically examining the current process of AE assessment, highlighting the need to incorporate patient reported outcomes, addressing issues unique to stem cell transplantation and survivorship, appraising challenges in regulatory approval and evaluating toxicity in real world patients.
